Cargando…

Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693

BACKGROUND: Inappropriate activation of AKT signaling is a relatively common occurrence in human tumors, and can be caused by activation of components of, or by loss or decreased activity of inhibitors of, this signaling pathway. A novel, pan AKT kinase inhibitor, GSK690693, was developed in order t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Rakesh, Blakemore, Stephen J, Ellis, Catherine E, Petricoin, Emanuel F, Pratt, Dexter, Macoritto, Michael, Matthews, Andrea L, Loureiro, Joseph J, Elliston, Keith
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996947/
https://www.ncbi.nlm.nih.gov/pubmed/20604938
http://dx.doi.org/10.1186/1471-2164-11-419
_version_ 1782193241174573056
author Kumar, Rakesh
Blakemore, Stephen J
Ellis, Catherine E
Petricoin, Emanuel F
Pratt, Dexter
Macoritto, Michael
Matthews, Andrea L
Loureiro, Joseph J
Elliston, Keith
author_facet Kumar, Rakesh
Blakemore, Stephen J
Ellis, Catherine E
Petricoin, Emanuel F
Pratt, Dexter
Macoritto, Michael
Matthews, Andrea L
Loureiro, Joseph J
Elliston, Keith
author_sort Kumar, Rakesh
collection PubMed
description BACKGROUND: Inappropriate activation of AKT signaling is a relatively common occurrence in human tumors, and can be caused by activation of components of, or by loss or decreased activity of inhibitors of, this signaling pathway. A novel, pan AKT kinase inhibitor, GSK690693, was developed in order to interfere with the inappropriate AKT signaling seen in these human malignancies. Causal network modeling is a systematic computational analysis that identifies upstream changes in gene regulation that can serve as explanations for observed changes in gene expression. In this study, causal network modeling is employed to elucidate mechanisms of action of GSK690693 that contribute to its observed biological effects. The mechanism of action of GSK690693 was evaluated in multiple human tumor cell lines from different tissues in 2-D cultures and xenografts using RNA expression and phosphoproteomics data. Understanding the molecular mechanism of action of novel targeted agents can enhance our understanding of various biological processes regulated by the intended target and facilitate their clinical development. RESULTS: Causal network modeling on transcriptomic and proteomic data identified molecular networks that are comprised of activated or inhibited mechanisms that could explain observed changes in the sensitive cell lines treated with GSK690693. Four networks common to all cell lines and xenografts tested were identified linking GSK690693 inhibition of AKT kinase activity to decreased proliferation. These networks included increased RB1 activity, decreased MYC activity, decreased TFRC activity, and increased FOXO1/FOXO3 activity. CONCLUSION: AKT is involved in regulating both cell proliferation and apoptotic pathways; however, the primary effect with GSK690693 appears to be anti-proliferative in the cell lines and xenografts evaluated. Furthermore, these results indicate that anti-proliferative responses to GSK690693 in either 2-D culture or xenograft models may share common mechanisms within and across sensitive cell lines.
format Text
id pubmed-2996947
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29969472010-12-07 Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693 Kumar, Rakesh Blakemore, Stephen J Ellis, Catherine E Petricoin, Emanuel F Pratt, Dexter Macoritto, Michael Matthews, Andrea L Loureiro, Joseph J Elliston, Keith BMC Genomics Research Article BACKGROUND: Inappropriate activation of AKT signaling is a relatively common occurrence in human tumors, and can be caused by activation of components of, or by loss or decreased activity of inhibitors of, this signaling pathway. A novel, pan AKT kinase inhibitor, GSK690693, was developed in order to interfere with the inappropriate AKT signaling seen in these human malignancies. Causal network modeling is a systematic computational analysis that identifies upstream changes in gene regulation that can serve as explanations for observed changes in gene expression. In this study, causal network modeling is employed to elucidate mechanisms of action of GSK690693 that contribute to its observed biological effects. The mechanism of action of GSK690693 was evaluated in multiple human tumor cell lines from different tissues in 2-D cultures and xenografts using RNA expression and phosphoproteomics data. Understanding the molecular mechanism of action of novel targeted agents can enhance our understanding of various biological processes regulated by the intended target and facilitate their clinical development. RESULTS: Causal network modeling on transcriptomic and proteomic data identified molecular networks that are comprised of activated or inhibited mechanisms that could explain observed changes in the sensitive cell lines treated with GSK690693. Four networks common to all cell lines and xenografts tested were identified linking GSK690693 inhibition of AKT kinase activity to decreased proliferation. These networks included increased RB1 activity, decreased MYC activity, decreased TFRC activity, and increased FOXO1/FOXO3 activity. CONCLUSION: AKT is involved in regulating both cell proliferation and apoptotic pathways; however, the primary effect with GSK690693 appears to be anti-proliferative in the cell lines and xenografts evaluated. Furthermore, these results indicate that anti-proliferative responses to GSK690693 in either 2-D culture or xenograft models may share common mechanisms within and across sensitive cell lines. BioMed Central 2010-07-06 /pmc/articles/PMC2996947/ /pubmed/20604938 http://dx.doi.org/10.1186/1471-2164-11-419 Text en Copyright ©2010 Kumar et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kumar, Rakesh
Blakemore, Stephen J
Ellis, Catherine E
Petricoin, Emanuel F
Pratt, Dexter
Macoritto, Michael
Matthews, Andrea L
Loureiro, Joseph J
Elliston, Keith
Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693
title Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693
title_full Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693
title_fullStr Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693
title_full_unstemmed Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693
title_short Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693
title_sort causal reasoning identifies mechanisms of sensitivity for a novel akt kinase inhibitor, gsk690693
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996947/
https://www.ncbi.nlm.nih.gov/pubmed/20604938
http://dx.doi.org/10.1186/1471-2164-11-419
work_keys_str_mv AT kumarrakesh causalreasoningidentifiesmechanismsofsensitivityforanovelaktkinaseinhibitorgsk690693
AT blakemorestephenj causalreasoningidentifiesmechanismsofsensitivityforanovelaktkinaseinhibitorgsk690693
AT elliscatherinee causalreasoningidentifiesmechanismsofsensitivityforanovelaktkinaseinhibitorgsk690693
AT petricoinemanuelf causalreasoningidentifiesmechanismsofsensitivityforanovelaktkinaseinhibitorgsk690693
AT prattdexter causalreasoningidentifiesmechanismsofsensitivityforanovelaktkinaseinhibitorgsk690693
AT macorittomichael causalreasoningidentifiesmechanismsofsensitivityforanovelaktkinaseinhibitorgsk690693
AT matthewsandreal causalreasoningidentifiesmechanismsofsensitivityforanovelaktkinaseinhibitorgsk690693
AT loureirojosephj causalreasoningidentifiesmechanismsofsensitivityforanovelaktkinaseinhibitorgsk690693
AT ellistonkeith causalreasoningidentifiesmechanismsofsensitivityforanovelaktkinaseinhibitorgsk690693